Tretinoin Embryopathy: Risks and Clinical Management

Teratogenic Effects and Risk Comparison

The risk of tretinoin embryopathy appears highest during weeks 3-6 of gestation, which corresponds to critical periods of embryonic development 1

For women of childbearing potential, pregnancy must be excluded by negative pregnancy test within 2 weeks prior to starting therapy, and effective contraception must be practiced for at least 4 weeks before and during therapy, as recommended by the British Journal of Dermatology 2
Patients should not donate blood either during or for at least 1 year following discontinuation of therapy, according to guidelines from the British Journal of Dermatology 2

For pregnant women with accidental exposure, comprehensive evaluation including detailed ultrasound examination is recommended to detect possible malformations, as suggested by the American family physician 4
For skin conditions typically treated with tretinoin, safer alternatives should be considered for pregnant women, and beta-carotene form of vitamin A is preferred over retinol during pregnancy, according to the American family physician 4

The American Academy of Dermatology recommends discontinuing retinoids at least 1 month before attempting conception, highlighting the importance of absolute avoidance of all retinoids during pregnancy 3
Even with risk management programs, fetal exposures continue to occur, highlighting the importance of absolute avoidance of all retinoids during pregnancy, as noted by the Journal of the American Academy of Dermatology 5